S&P 500   4,967.23
DOW   37,986.40
QQQ   414.65
How major US stock indexes fared Friday, 4/19/2024
Biden signs bill extending a key US surveillance program after divisions nearly forced it to lapse
MarketBeat Week in Review – 4/15 - 4/19
The drug war devastated Black and other minority communities. Is marijuana legalization helping?
Morning sickness? Prenatal check-ups? What to know about new rights for pregnant workers
A man escaped Sudan's bloody civil war. His mysterious death in Missisippi has sparked suspicion
Record Store Day celebrates indie retail music sellers as they ride vinyl's popularity wave
S&P 500   4,967.23
DOW   37,986.40
QQQ   414.65
How major US stock indexes fared Friday, 4/19/2024
Biden signs bill extending a key US surveillance program after divisions nearly forced it to lapse
MarketBeat Week in Review – 4/15 - 4/19
The drug war devastated Black and other minority communities. Is marijuana legalization helping?
Morning sickness? Prenatal check-ups? What to know about new rights for pregnant workers
A man escaped Sudan's bloody civil war. His mysterious death in Missisippi has sparked suspicion
Record Store Day celebrates indie retail music sellers as they ride vinyl's popularity wave
S&P 500   4,967.23
DOW   37,986.40
QQQ   414.65
How major US stock indexes fared Friday, 4/19/2024
Biden signs bill extending a key US surveillance program after divisions nearly forced it to lapse
MarketBeat Week in Review – 4/15 - 4/19
The drug war devastated Black and other minority communities. Is marijuana legalization helping?
Morning sickness? Prenatal check-ups? What to know about new rights for pregnant workers
A man escaped Sudan's bloody civil war. His mysterious death in Missisippi has sparked suspicion
Record Store Day celebrates indie retail music sellers as they ride vinyl's popularity wave
S&P 500   4,967.23
DOW   37,986.40
QQQ   414.65
How major US stock indexes fared Friday, 4/19/2024
Biden signs bill extending a key US surveillance program after divisions nearly forced it to lapse
MarketBeat Week in Review – 4/15 - 4/19
The drug war devastated Black and other minority communities. Is marijuana legalization helping?
Morning sickness? Prenatal check-ups? What to know about new rights for pregnant workers
A man escaped Sudan's bloody civil war. His mysterious death in Missisippi has sparked suspicion
Record Store Day celebrates indie retail music sellers as they ride vinyl's popularity wave
NASDAQ:NAUT

Nautilus Biotechnology (NAUT) Stock Price, News & Analysis

$2.46
+0.12 (+5.13%)
(As of 04/19/2024 ET)
Today's Range
$2.31
$2.46
50-Day Range
$2.34
$3.06
52-Week Range
$2.16
$4.65
Volume
52,503 shs
Average Volume
63,740 shs
Market Capitalization
$307.75 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$6.00

Nautilus Biotechnology MarketRank™ Stock Analysis

Analyst Rating
Hold
2.00 Rating Score
Upside/​Downside
143.9% Upside
$6.00 Price Target
Short Interest
Bearish
2.11% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
N/A
Insider Trading
Acquiring Shares
$108,316 Bought Last Quarter
Proj. Earnings Growth
Decreasing
From ($0.72) to ($0.82) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

1.68 out of 5 stars

Medical Sector

644th out of 911 stocks

Analytical Instruments Industry

22nd out of 25 stocks

NAUT stock logo

About Nautilus Biotechnology Stock (NASDAQ:NAUT)

Nautilus Biotechnology, Inc., a development stage life sciences company, engages in creating a platform technology for quantifying and unlocking the complexity of the proteome. The company develops Nautilus Platform, a proteomics platform that includes end-to-end solution comprised of instruments, consumables, and software analysis. It also offers proteome analysis system, a high-resolution optical imaging system for integrated fluidics and liquid handling sub-system. In addition, the company provides sample preparation, flow cells, multi-affinity probe reagents, and instrument buffers system to perform multi-cycle analysis runs. Nautilus Biotechnology, Inc. was incorporated in 2016 and is headquartered in Seattle, Washington.

NAUT Stock Price History

NAUT Stock News Headlines

Nautilus Biotechnology Inc Ordinary Shares NAUT
The “Perfect Storm” for Gold
Gold has already reached all-time highs, and experts believe it's not slowing down any time soon. In fact, some analysts predict a $7,000 price tag by 2025.
Q4 2023 Nautilus Biotechnology Inc Earnings Call
The “Perfect Storm” for Gold
Gold has already reached all-time highs, and experts believe it's not slowing down any time soon. In fact, some analysts predict a $7,000 price tag by 2025.
Nautilus Biotechnology Inc Ordinary Shares
Nautilus Biotechnology Inc.
See More Headlines
Receive NAUT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Nautilus Biotechnology and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
2/28/2024
Today
4/20/2024
Next Earnings (Confirmed)
4/30/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Analytical instruments
Sub-Industry
N/A
Current Symbol
NASDAQ:NAUT
Fax
N/A
Employees
167
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$6.00
High Stock Price Target
$6.00
Low Stock Price Target
$6.00
Potential Upside/Downside
+143.9%
Consensus Rating
Hold
Rating Score (0-4)
2.00
Research Coverage
1 Analysts

Profitability

Net Income
$-63,670,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$2.12 per share

Miscellaneous

Free Float
71,931,000
Market Cap
$307.75 million
Optionable
Optionable
Beta
1.20
5G Stocks: The Path Forward is Profitable Cover

Click the link below and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.

Get This Free Report

NAUT Stock Analysis - Frequently Asked Questions

Should I buy or sell Nautilus Biotechnology stock right now?

1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Nautilus Biotechnology in the last year. There are currently 1 hold rating for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" NAUT shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in NAUT, but not buy additional shares or sell existing shares.
View NAUT analyst ratings
or view top-rated stocks.

What is Nautilus Biotechnology's stock price target for 2024?

1 equities research analysts have issued 1-year target prices for Nautilus Biotechnology's shares. Their NAUT share price targets range from $6.00 to $6.00. On average, they predict the company's share price to reach $6.00 in the next twelve months. This suggests a possible upside of 143.9% from the stock's current price.
View analysts price targets for NAUT
or view top-rated stocks among Wall Street analysts.

How have NAUT shares performed in 2024?

Nautilus Biotechnology's stock was trading at $2.99 at the beginning of the year. Since then, NAUT shares have decreased by 17.7% and is now trading at $2.46.
View the best growth stocks for 2024 here
.

When is Nautilus Biotechnology's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, April 30th 2024.
View our NAUT earnings forecast
.

How can I listen to Nautilus Biotechnology's earnings call?

Nautilus Biotechnology will be holding an earnings conference call on Tuesday, April 30th at 8:30 AM Eastern. Interested parties can register for or listen to the call using this link.

How were Nautilus Biotechnology's earnings last quarter?

Nautilus Biotechnology, Inc. (NASDAQ:NAUT) released its quarterly earnings data on Wednesday, February, 28th. The company reported ($0.14) earnings per share for the quarter, topping the consensus estimate of ($0.16) by $0.02. During the same quarter last year, the firm earned ($0.11) earnings per share.

How do I buy shares of Nautilus Biotechnology?

Shares of NAUT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:NAUT) was last updated on 4/20/2024 by MarketBeat.com Staff

From Our Partners